If a coronavirus vaccine is available, who will be vaccinated first? The question is currently being studied.
In an interview with Sudinfo, the inter-federal spokesperson Yves Van Laethem explains that this vaccine will not be accessible to everyone.“We are really at the premises and we are moving forward in an abstract way since no one has yet data on the first vaccine that will be released, its characteristics, etc. However, what is certain is that it does not There will not be for everyone. Logical since we start from 0 and that all countries will rush on! The most optimistic speak of a few million vaccines on the market for the end of autumn 2020. C ‘ is really peanuts for a world population of 7 billion people! Then other vaccines could arrive in spring or early summer 2021, he says.
3 priority groups
Before adding: “Belgium will have to position itself well to obtain these vaccines, unless Europe launches group purchases. Something seems to tremble on this side. Anyway, we will not be able to vaccinate all Belgian population. Priority groups will have to be determined “.
The inter-federal spokesperson for the fight against covid 19 Yves Van Laethem indicates that the Superior Council of Health plans to vaccinate as a priority three groups of people: those over 65, people with hypertension or diabetes and nursing staff.
The federal government has released 20 million euros for a project to accelerate the development of vaccines, uniting the universities of Antwerp and Brussels, reported on Monday De Morgen, De Standaard and Le Soir. Belgium is investing in this way to prepare for the next pandemic.
> CORONAVIRUS in Belgium: the latest news
The Council of Ministers decided over the weekend to invest 20 million in the creation of an Infectious Disease Control Unit. It will bring together the expertise of the Free University of Brussels and the University of Antwerp. This project, for a total amount of 40 million euros, aims to equip Belgium – and more generally Europe – with the weapons necessary to combat the emergence of the next pandemic, by developing tools that will accelerate strongly development of vaccines and tests. The other 20 million will come from the private sector, but not from the pharmaceutical industry.
– .
